Jim Cramer, the host of CNBC’s “Mad Money,” is known for his energetic and often controversial takes on the stock market.

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...

Mullen team present in Dubai this week for delivery of first EV vehicles. Mullen recently executed a 1-for-100 reverse stock ...

Gartner IT has outperformed the market over the past 15 years by 13.06% on an annualized basis producing an average annual ...

The union members, most of them based in Washington state, turned down a proposal to raise wages by 25% over four years, as ...

FDA approves Elanco's once-daily oral treatment, Zenrelia, for controlling itching in dogs with allergic and atopic ...

Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose.

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $14.8, a high ...

A study reveals the potential use of cannabis in biblical times, suggesting Jesus used it for healing and anointing practices ...

Palantir announced a contract granted by the DEVCOM Army Research Laboratory that broadens Maven Smart System access across ...